University of Regensburg, Universitätsstraße 31, 93053, Regensburg, Germany.
Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Regensburg, Franz-Josef-Strauss Allee 11, 93053, Regensburg, Germany.
J Cancer Res Clin Oncol. 2023 Oct;149(13):12081-12087. doi: 10.1007/s00432-023-05122-1. Epub 2023 Jul 8.
Given the concerns about the effects of the COVID-19 pandemic on cancer care, we analyzed the treatment quality of the head and neck cancer center Regensburg before and throughout 2 years of the pandemic. We included data of 3 years to reflect the extended pandemic period as new developments continued to influence its course.
This retrospective review included all patients diagnosed with head and neck cancer in 2019, 2020, and 2021 who had not started treatment elsewhere prior to being referred to the head and neck cancer center. We compared tumor characteristics and times to therapy of patients diagnosed before COVID-19 in 2019 (n = 253), during COVID-19 in 2020 (n = 206), and in a phase of partial normalization in a persistent pandemic situation in 2021 (n = 247).
Our data revealed no decrease in diagnoses or drift in stages toward more advanced stages. There was an increased percentage of diagnoses confirmed at the head and neck cancer center from 2019 (57.3%) to 2020 (68.0%) and to 2021 (65.6%) compared to confirmation at other institutions (2019, 42.7%; 2020, 32.0%; 2021, 34.4%; P = 0.041). Surgery and radiotherapy were performed with the same frequency. The median days between diagnosis and surgery were decreased in 2020 (19.5 days; P = 0.049) and 2021 (20.0 days; P = 0.026) in comparison to 2019 (23 days). The days to radiotherapy were not affected.
The data indicate a consistent oncological performance for head and neck cancer patients in all waves of the pandemic and thereafter without a decrease in diagnoses or shift in stages.
鉴于人们对 COVID-19 大流行对癌症治疗影响的担忧,我们分析了雷根斯堡头颈部癌症中心在大流行期间及其前后 2 年的治疗质量。我们纳入了 3 年的数据,以反映大流行的延长阶段,因为新的发展继续影响其进程。
这项回顾性研究包括 2019 年、2020 年和 2021 年所有未在被转诊到头颈部癌症中心之前在其他地方开始治疗的头颈部癌症患者。我们比较了在 COVID-19 之前的 2019 年(n=253)、COVID-19 期间的 2020 年(n=206)和在持续大流行情况下部分恢复正常的 2021 年(n=247)诊断的患者的肿瘤特征和治疗时间。
我们的数据显示,诊断数量没有减少,也没有向更晚期阶段转移。在头颈部癌症中心确诊的患者比例从 2019 年(57.3%)增加到 2020 年(68.0%)和 2021 年(65.6%),而在其他机构确诊的患者比例从 2019 年(42.7%)、2020 年(32.0%)和 2021 年(34.4%)降低(P=0.041)。手术和放疗的频率相同。与 2019 年(23 天)相比,2020 年(19.5 天;P=0.049)和 2021 年(20.0 天;P=0.026)诊断后手术的中位时间缩短。放疗的天数没有受到影响。
这些数据表明,在大流行的所有浪潮及其后,头颈部癌症患者的肿瘤治疗表现一致,诊断数量没有减少,也没有向更晚期阶段转移。